Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality

Jennifer E Flythe, Stephen E Kimmel, Steven M Brunelli, Jennifer E Flythe, Stephen E Kimmel, Steven M Brunelli

Abstract

Patients receiving hemodialysis have high rates of cardiovascular morbidity and mortality that may be related to the hemodynamic effects of rapid ultrafiltration. Here we tested whether higher dialytic ultrafiltration rates are associated with greater all-cause and cardiovascular mortality, and hospitalization for cardiovascular disease. We used data from the Hemodialysis Study, an almost-7-year randomized clinical trial of 1846 patients receiving thrice-weekly chronic dialysis. The ultrafiltration rates were divided into three categories: up to 10 ml/h/kg, 10-13 ml/h/kg, and over 13 ml/h/kg. Compared to ultrafiltration rates in the lowest group, rates in the highest were significantly associated with increased all-cause and cardiovascular-related mortality with adjusted hazard ratios of 1.59 and 1.71, respectively. Overall, ultrafiltration rates between 10-13 ml/h/kg were not associated with all-cause or cardiovascular mortality; however, they were significantly associated among participants with congestive heart failure. Cubic spline interpolation suggested that the risk of all-cause and cardiovascular mortality began to increase at ultrafiltration rates over 10 ml/h/kg regardless of the status of congestive heart failure. Hence, higher ultrafiltration rates in hemodialysis patients are associated with a greater risk of all-cause and cardiovascular death.

Figures

Figure 1. Unadjusted and adjusted associations between…
Figure 1. Unadjusted and adjusted associations between ultrafiltration rate (UFR) and all-cause mortality based on Cox regression models
Multivariable models were adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit (

Figure 2. Unadjusted and adjusted associations between…

Figure 2. Unadjusted and adjusted associations between ultrafiltration rate (UFR) and cardiovascular (CV)-related mortality based…

Figure 2. Unadjusted and adjusted associations between ultrafiltration rate (UFR) and cardiovascular (CV)-related mortality based on Cox regression models
Multivariable models were adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit (

Figure 3. Cubic spline analysis of the…

Figure 3. Cubic spline analysis of the associations between ultrafiltration rate (UFR) and cardiovascular (CV)…

Figure 3. Cubic spline analysis of the associations between ultrafiltration rate (UFR) and cardiovascular (CV) (solid line) and all-cause (dashed line) mortality
Hazard ratios were adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit (

Figure 4. Adjusted association between ultrafiltration rate…

Figure 4. Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause…

Figure 4. Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause mortality, (2) CV hospitalization and CV-related mortality, and (3) CV hospitalization
Based on Cox regression models adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit ( 13 ml/h/kg, respectively) and outcomes were: 0.88 (0.76–1.03; P = 0.13) and 1.21 (1.05–1.40; P = 0.01) for CV hospitalization and all-cause mortality; 0.90 (0.76–1.08; P = 0.26) and 1.23 (1.05–1.45; P = 0.01) for CV hospitalization and CV-related mortality; and 0.88 (0.73–1.06; P = 0.18) and 1.14 (0.96–1.36; P = 0.13) for CV hospitalization. Abbreviations: ref., reference; CI, confidence interval.
Comment in
Similar articles
Cited by
References
    1. USRDS. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2008.
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119. - PubMed
    1. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315. - PubMed
    1. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118:1748–1757. - PubMed
    1. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218. - PubMed
Show all 31 references
Publication types
MeSH terms
Related information
[x]
Cite
Copy Download .nbib .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 2. Unadjusted and adjusted associations between…
Figure 2. Unadjusted and adjusted associations between ultrafiltration rate (UFR) and cardiovascular (CV)-related mortality based on Cox regression models
Multivariable models were adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit (

Figure 3. Cubic spline analysis of the…

Figure 3. Cubic spline analysis of the associations between ultrafiltration rate (UFR) and cardiovascular (CV)…

Figure 3. Cubic spline analysis of the associations between ultrafiltration rate (UFR) and cardiovascular (CV) (solid line) and all-cause (dashed line) mortality
Hazard ratios were adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit (

Figure 4. Adjusted association between ultrafiltration rate…

Figure 4. Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause…

Figure 4. Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause mortality, (2) CV hospitalization and CV-related mortality, and (3) CV hospitalization
Based on Cox regression models adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit ( 13 ml/h/kg, respectively) and outcomes were: 0.88 (0.76–1.03; P = 0.13) and 1.21 (1.05–1.40; P = 0.01) for CV hospitalization and all-cause mortality; 0.90 (0.76–1.08; P = 0.26) and 1.23 (1.05–1.45; P = 0.01) for CV hospitalization and CV-related mortality; and 0.88 (0.73–1.06; P = 0.18) and 1.14 (0.96–1.36; P = 0.13) for CV hospitalization. Abbreviations: ref., reference; CI, confidence interval.
Comment in
Similar articles
Cited by
References
    1. USRDS. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2008.
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119. - PubMed
    1. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315. - PubMed
    1. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118:1748–1757. - PubMed
    1. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218. - PubMed
Show all 31 references
Publication types
MeSH terms
Related information
[x]
Cite
Copy Download .nbib .nbib
Format: AMA APA MLA NLM
Figure 3. Cubic spline analysis of the…
Figure 3. Cubic spline analysis of the associations between ultrafiltration rate (UFR) and cardiovascular (CV) (solid line) and all-cause (dashed line) mortality
Hazard ratios were adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit (

Figure 4. Adjusted association between ultrafiltration rate…

Figure 4. Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause…

Figure 4. Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause mortality, (2) CV hospitalization and CV-related mortality, and (3) CV hospitalization
Based on Cox regression models adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit ( 13 ml/h/kg, respectively) and outcomes were: 0.88 (0.76–1.03; P = 0.13) and 1.21 (1.05–1.40; P = 0.01) for CV hospitalization and all-cause mortality; 0.90 (0.76–1.08; P = 0.26) and 1.23 (1.05–1.45; P = 0.01) for CV hospitalization and CV-related mortality; and 0.88 (0.73–1.06; P = 0.18) and 1.14 (0.96–1.36; P = 0.13) for CV hospitalization. Abbreviations: ref., reference; CI, confidence interval.
Figure 4. Adjusted association between ultrafiltration rate…
Figure 4. Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause mortality, (2) CV hospitalization and CV-related mortality, and (3) CV hospitalization
Based on Cox regression models adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage ( 200 ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum albumin, creatinine, hematocrit ( 13 ml/h/kg, respectively) and outcomes were: 0.88 (0.76–1.03; P = 0.13) and 1.21 (1.05–1.40; P = 0.01) for CV hospitalization and all-cause mortality; 0.90 (0.76–1.08; P = 0.26) and 1.23 (1.05–1.45; P = 0.01) for CV hospitalization and CV-related mortality; and 0.88 (0.73–1.06; P = 0.18) and 1.14 (0.96–1.36; P = 0.13) for CV hospitalization. Abbreviations: ref., reference; CI, confidence interval.

References

    1. USRDS. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2008.
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119.
    1. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315.
    1. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118:1748–1757.
    1. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218.
    1. Shoji T, Tsubakihara Y, Fujii M, et al. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212–1220.
    1. John AS, Tuerff SD, Kerstein MD. Nonocclusive mesenteric infarction in hemodialysis patients. J Am Coll Surg. 2000;190:84–88.
    1. Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4:914–920.
    1. Cotter G, Felker GM, Adams KF, et al. The pathophysiology of acute heart failure—is it all about fluid accumulation? Am Heart J. 2008;155:9–18.
    1. Sharpe N. Left ventricular remodeling: pathophysiology and treatment. Heart Fail Monit. 2003;4:55–61.
    1. Martin LC, Franco RJ, Gavras I, et al. Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens. 2004;17:1163–1169.
    1. Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol. 2008;3:920–929.
    1. Zoccali C, Benedetto FA, Tripepi G, et al. Cardiac consequences of hypertension in hemodialysis patients. Semin Dial. 2004;17:299–303.
    1. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4(Suppl 1):S79–S91.
    1. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006;69:1222–1228.
    1. Movilli E, Gaggia P, Zubani R, et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant. 2007;22:3547–3552.
    1. Greene T, Beck GJ, Gassman JJ, et al. Design and statistical issues of the Hemodialysis (HEMO) Study. Control Clin Trials. 2000;21:502–525.
    1. Lilley JJ, Golden J, Stone RA. Adrenergic regulation of blood pressure in chronic renal failure. J Clin Invest. 1976;57:1190–1200.
    1. Friess U, Rascher W, Ritz E, et al. Failure of arginine-vasopressin and other pressor hormones to increase in severe recurrent dialysis hypotension. Nephrol Dial Transplant. 1995;10:1421–1427.
    1. Daul AE, Wang XL, Michel MC, et al. Arterial hypotension in chronic hemodialyzed patients. Kidney Int. 1987;32:728–735.
    1. Converse RL, Jr, Jacobsen TN, Jost CM, et al. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest. 1992;90:1657–1665.
    1. Nette RW, van den Dorpel MA, Krepel HP, et al. Hypotension during hemodialysis results from an impairment of arteriolar tone and left ventricular function. Clin Nephrol. 2005;63:276–283.
    1. Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol. 2009;4:1925–1931.
    1. Selby NM, Burton JO, Chesterton LJ, et al. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol. 2006;1:1216–1225.
    1. Selby NM, Lambie SH, Camici PG, et al. Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis. 2006;47:830–841.
    1. Shivalkar B, Flameng W, Szilard M, et al. Repeated stunning precedes myocardial hibernation in progressive multiple coronary artery obstruction. J Am Coll Cardiol. 1999;34:2126–2136.
    1. Sharp J, Wild MR, Gumley AI, et al. A cognitive behavioral group approach to enhance adherence to hemodialysis fluid restrictions: a randomized controlled trial. Am J Kidney Dis. 2005;45:1046–1057.
    1. Bame SI, Petersen N, Wray NP. Variation in hemodialysis patient compliance according to demographic characteristics. Soc Sci Med. 1993;37:1035–1043.
    1. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int. 2007;71:349–359.
    1. Gura V, Macy AS, Beizai M, et al. Technical breakthroughs in the wearable artificial kidney (WAK) Clin J Am Soc Nephrol. 2009;4:1441–1448.
    1. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019.

Source: PubMed

Подписаться